Sachs Associates

Rajarshi Banerjee is the CEO of Perspectum Ltd and a practicing consultant in medicine in Oxford. Perspectum is a precision health company dedicated to improving the diagnosis, treatment, and management of metabolic diseases and cancer. Rajarshi graduated from Oxford with a degree in medicine in 2002, later moving to London to complete his general medical training and a specialist registrar rotation in general medicine and cardiology. ‘At the coalface’ in medical admission units and cardiology wards there was an alarming rise in the prevalence of coexistent cardiovascular and liver disease, driven by obesity and alcohol use, which fostered his interest in acquired cardiovascular disease. He was awarded a British Heart Foundation Clinical Research Training Fellowship in 2008 to study the effects of excess weight on the cardiovascular system. In 2011, using new MR techniques developed in and patented by the Oxford Centre for Clinical Magnetic Resonance (OCMR), he began the Rapid Imaging in Liver Disease (RIAL) study in collaboration with the Translational Gastroenterology Unit, to see if advances in MR could enable better diagnosis and monitoring of liver disease, using liver biopsy as a reference standard. The study showed a high diagnostic accuracy for each of liver fat, fibrosis and iron content. The tissue characterisation techniques first used here have now become widely adopted in the assessment of liver disease and have been referenced in many publications. In 2024, Perspectum was acknowledged as the best established MedTech company in Oxfordshire. Meet Rajarshi Banerjee @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth

Clément Gautier is the Head of External Innovation for Ipsen, leading efforts in Rare Diseases and Neuroscience. A global biopharmaceutical company, Ipsen is committed to delivering transformative therapies for patients with neurological disorders with the highest unmet medical needs. Clément's teams play a pivotal role in driving Ipsen's mission by sourcing groundbreaking innovations exclusively through external partnerships. Meet Clément Gautier @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

Lipidio is a clinical stage company focused on developing a unique approach to treating systemic metabolic diseases by targeting the neuro-endocrine properties of skin. Our lead asset, GDD3898, is a Phase 2-ready obesity drug which acts by increasing energy expenditure with preclinical efficacy equivalent to GLP-1 agonists but without muscle loss. Meet Lipidio Pharmaceuticals @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth

Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025. Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including EQT, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises. Meet Noema Pharma AG @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

Antje Körner is a pediatrician-scientist, who has made major scientific contributions to the understanding of origin and consequences of childhood obesity and is utilizing the research to overcome the treatment gap for children living with obesity. She is appointed Professor of Metabolic Research and head of Childhood Obesity and Metabolic Research at HI-MAG & the Medical Faculty of Leipzig University and of the Pediatric Research Unit at Leipzig University Children´s Hospital. Originating from former East Germany, she had trained for data processing before entering Medical School. After pediatric residency she became consultant in pediatric endocrinology and heads the Obesity team. She engaged in obesity research with research stays at the National Instituts of Health (Bethesda) and the German Diabetes Center (Düsseldorf). In 2010 she had been first appointed as Professor of Pediatric Research, at that time youngest and the first female professor in the pediatric field at Leipzig University. Her research focusses to explore innovative avenues to understand what drives obesity in children, the mechanisms behind the clinical associations and foster early detection and pre/intervention for progressive childhood obesity following a holistic translational approach integrating experimental science, epidemiologic and clinical approaches. Her scientific achievements include the identification of early childhood as critical window for sustained obesity, rethinking risk definition and prediction of metabolic complications and identification of a new genetic obesity trait. It is her ambition to overcome the treatment gap in pediatric obesity through risk-profiling and understanding of mechanisms. She established unique populational and patient cohorts and has pioneered clinical trials for obesity treatment in Germany. She has received numerous prestigious national and international awards, the latest the EASO-Novo Nordisk Foundation Obesity Prize for Excellence. She has published >300 papers and her visibility is reflected by 60 publications with >60 citations. She has been instrumental in establishment of several research collaborative initiatives as co-chair/member of BoD. She is director of the Leipzig/Dresden partner site of the German Center for Child Health (DZKJ) and coordinates the research areas obesity/metabolism and Early determinants. Meet Prof. Antje Körner @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth Helmholtz Munich

Christopher Reyes, PhD, currently serves as the Chief Executive Officer and Director of Bloom Science, Inc., a company he co-founded that has a stated mission to develop novel therapeutics for patients with metabolic and neurological disorders. He is a biophysicist and entrepreneur with a passion for creating solutions to improve our health, environment and economic sustainability. Prior to Bloom Science, he served as global head and VP of Biologics at Bionomics. He co-founded and served as CSO and Director at Eclipse Therapeutics, a spin-out of Biogen IDEC, prior to its acquisition; and Scientist at Biogen-IDEC. Dr. Reyes has a Ph.D. in Biophysics at the University of California, San Francisco and B.A. in Molecular and Cell Biology, Biophysics from the University of California, Berkeley. Dr. Reyes was a postdoctoral fellow at The Scripps Research Institute. Dr. Reyes is a member of the Society for Advancement of Chicanos/Hispanics and Native Americans in Science. Meet Christopher Reyes, PhD @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

"Beyond Incretins: Canary Cure's CCT-217 Dual siRNA Gene Silencing Therapy Offers a Novel Approach to Obesity with Superior Fat Loss, Increase in Lean Muscle and Improved Body Composition: Canary Cure Biotechnologies, a late stage pre-clinical company, is tackling the growing obesity and diabetes crisis with CCT-217, a first-in-class dual siRNA gene precision therapy. Our pioneering approach offers a significant advancement over existing treatments, focusing on precise targeting and durable effects.  Studies show CCT-217's innovative mechanism of action reprograms white fat cells leading to more metabolically active brown fat, leading to a remarkable 25% increase in lean muscle mass while simultaneously reducing fat mass and increasing resting energy expenditure. This not only promotes weight loss but also improves metabolic function and overall health.  What sets CCT-217 apart is its unique ability to preserve lean body mass, a crucial factor often overlooked by current therapies. This proactive approach ensures healthier and more sustainable weight loss, addressing a critical unmet need in the obesity treatment landscape.  Furthermore, CCT-217's potential for twice-annual, self-administered dosing offers unparalleled convenience and patient compliance. This long-acting profile, combined with its targeted action and impressive efficacy, positions CCT-217 as a game-changer in the $200 Billion ( by 2030) Obesity treatment market.  Invest in Canary Cure's therapeutic development and support our mission to revolutionize metabolic disease management with CCT-217, a breakthrough therapy poised to redefine the future of obesity care. Meet Canary Cure Therapeutics @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth"

Claude Cohen-Bacrie is an entrepreneur in Medtech and founded two innovative companies in the field of ultrasound imaging. He was co-founder of SuperSonic imagine in 2005, and acted as executive vice president, Chief Technology Officer and Chief Operating Officer of the company until end 2017. Company was IPOed in 2014 and acquired by Hologic in 2019. In 2018, Claude founded E-Scopics, a point of care ultrasound company, which aims at democratizing the role of ultrasound toward all healthcare professionals ultimately. The company owns and develops proprietary technologies to allow dematerialization of ultrasound imaging architectures for innovative devices with strong clinical and technical differentiations within the point of care market. Its first product, Hepatoscope, is an ultraportable ultrasound imaging tool that enable Liver Stiffness Measurement and Quantitative Ultrasound to assess Liver Steatosis and Fibrosis at point of care for MASH screening and monitoring. Hepatoscope is FDA cleared and CE marked and is available commercially under a SaaS subscription model to spread its use for chronic liver diseases management over the continuum of care from Hepatology & Gastroenterology to Diabetology and up to primary care. Meet Claude COHEN-BACRIE @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth

Dr. Lombardo is Chief Executive Officer of Noema Pharma AG. She is a seasoned biopharma executive with more than 25 years of experience in the CNS space, spanning clinical practice, academic research, large pharma and biotech. She joined Noema Pharma’s Board of Directors in 2021, and transitioned to CEO in 2023. In 2019, Dr Lombardo co-founded Arvelle Therapeutics where she served as Chief Medical Officer. Dr. Lombardo was instrumental in building Arvelle into a launch-ready European CNS company, which was acquired by Angelini Pharma in 2021. Prior to joining Noema Pharma, Dr. Lombardo was President of the Therapeutics Division at gene therapy company Kriya Therapeutics. She has also held senior roles in clinical and medical development at Pfizer, Forum Pharmaceuticals and Axovant Sciences. She was previously on the faculty of Columbia University College of Physicians and Surgeons. Dr. Lombardo completed two fellowships, one in neuroreceptor imaging and one in molecular genetics. She completed her residency in psychiatry at Columbia University, and obtained her medical degree from Yale University, an M. Phil from the University of Cambridge and a bachelor’s degree from Brown University. Meet Ilise Lombardo @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

Dr. Acosta is a physician, scientist, inventor, and entrepreneur. He is board certified in Internal Medicine, Gastroenterology and Hepatology, and Obesity Medicine and Nutrition. Dr. Acosta holds an MD from Universidad San Francisco De Quito, Ecuador, and a PhD from University of Florida, Gainesville. Currently, he is an Associate Professor of Medicine and Consultant in Gastroenterology and Hepatology at the Mayo Clinic, Rochester, MN. He co-directs the Nutrition Obesity Research Program and directs the Precision Medicine for Obesity Program at Mayo Clinic. Dr. Acosta's goal is to treat and ultimately cure obesity, which he considers this century's health epidemic. Dr. Acosta's research focus on precision medicine for obesity with the aim to identify the right therapy for the right patient, minimizing side effects. His research is supported by the National Institute of Health, many foundations and industry. He is a recognized national and international speaker with many patents, more than 140 peer reviewed publications, including publications in the Lancet, Gut and Gastroenterology, and many book chapters. His works has been featured in the New York Times, Time, CNN, NPR, among others. He won the 40-under-40 innovation award at Minneapolis Business Journal 2020 and Tekne Award (Winners exemplify Technology Innovation in Minnesota). Meet Andres Acosta M.D., Ph.D. @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth